UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

OX40 is a potent immune-stimulating target in late-stage cancer patients

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24), p.7189-7198

2013

Volltextzugriff (PDF)

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

Nature communications, 2021-02, Vol.12 (1), p.1047-1047, Article 1047

2021

Volltextzugriff (PDF)

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Annals of the New York Academy of Sciences, 2013-07, Vol.1291 (1), p.1-13

2013

Volltextzugriff (PDF)

Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses

Science translational medicine, 2012-06, Vol.4 (137), p.137ra74

2012

Volltextzugriff (PDF)

Efficient Cross-presentation Depends on Autophagy in Tumor Cells

Cancer research (Chicago, Ill.), 2008-09, Vol.68 (17), p.6889-6895

2008

Volltextzugriff (PDF)

Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance

Journal for immunotherapy of cancer, 2019-07, Vol.7 (1), p.165-11, Article 165

2019

Volltextzugriff (PDF)

Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer

Breast cancer research : BCR, 2021-01, Vol.23 (1), p.2-2, Article 2

2021

Volltextzugriff (PDF)

Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma

Journal for immunotherapy of cancer, 2021-05, Vol.9 (5), p.e002485

2021

Volltextzugriff (PDF)

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response

Journal for immunotherapy of cancer, 2020-05, Vol.8 (1), p.e000930

2020

Volltextzugriff (PDF)

Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy

Clinical cancer research, 2011-11, Vol.17 (22), p.7047-7057

2011

Volltextzugriff (PDF)

Science gone translational: the OX40 agonist story

Immunological reviews, 2011-11, Vol.244 (1), p.218-231

2011

Volltextzugriff (PDF)

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment

Journal of translational medicine, 2013-03, Vol.11 (1), p.54-54, Article 54

2013

Volltextzugriff (PDF)

Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma

Journal for immunotherapy of cancer, 2015-10, Vol.3 (1), p.47-47, Article 47

2015

Volltextzugriff (PDF)

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2005-01, Vol.23 (1), p.133-141

2005

Volltextzugriff (PDF)

Granulocyte Macrophage Colony-Stimulating Factor–Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer

Clinical cancer research, 2007-07, Vol.13 (13), p.3883-3891

2007

Volltextzugriff (PDF)

Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer

The New England journal of medicine, 2022-06, Vol.386 (22), p.2112-2119

2022

Volltextzugriff (PDF)

Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma

Journal for immunotherapy of cancer, 2020-05, Vol.8 (1), p.e000773

2020

Volltextzugriff (PDF)

Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. Reply

The New England journal of medicine, 2022-08, Vol.387 (6), p.574-574

2022

Volltextzugriff (PDF)

Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program

Journal for immunotherapy of cancer, 2014-05, Vol.2 (1), p.13-13

2014

Volltextzugriff (PDF)

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

Journal for immunotherapy of cancer, 2021-10, Vol.9 (10), p.e002663

2021

Volltextzugriff (PDF)

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Cell, 2017-11, Vol.171 (4), p.934-949.e16

2017

Volltextzugriff (PDF)

Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40

Clinical cancer research, 2017-10, Vol.23 (20), p.6165-6177

2017

Volltextzugriff (PDF)

Targeting Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) : A Novel Strategy for the Treatment of Melanoma and Other Malignancies

Cancer, 2007-12, Vol.110 (12), p.2614-2627

2007

Volltextzugriff (PDF)

A Milestone for CAR T Cells

The New England journal of medicine, 2017-12, Vol.377 (26), p.2593-2596

2017

Volltextzugriff (PDF)

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma

Journal of clinical oncology, 2008-05, Vol.26 (14), p.2292-2298

2008

Volltextzugriff (PDF)

1 – 25 von 261

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(255)
Mit Volltextzugriff
(222)

Publikationsform

Artikel
(260)
Reviews
(1)

Sprache

Englisch
(261)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

OX40 is a potent immune-stimulating target in late-stage cancer patients

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses

Efficient Cross-presentation Depends on Autophagy in Tumor Cells

Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance

Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer

Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response

Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy

Science gone translational: the OX40 agonist story

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment

Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

Granulocyte Macrophage Colony-Stimulating Factor–Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer

Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer

Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma

Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. Reply

Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40

Targeting Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) : A Novel Strategy for the Treatment of Melanoma and Other Malignancies

A Milestone for CAR T Cells

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma

Suchergebnisse filtern